Celularity Inc. (NASDAQ:CELU) Short Interest Up 50.0% in March

Celularity Inc. (NASDAQ:CELU) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 1,560,000 shares, an increase of 50.0% from the February 28th total of 1,040,000 shares. Approximately 11.9% of the shares of the stock are short sold. Based on an average daily volume of 159,900 shares, the short-interest ratio is presently 9.8 days.

Hedge Funds Weigh In On Celularity

A number of hedge funds and other institutional investors have recently modified their holdings of CELU. Keynote Financial Services LLC lifted its stake in Celularity by 90.1% in the 4th quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock worth $52,000 after purchasing an additional 11,863 shares in the last quarter. Biltmore Family Office LLC bought a new stake in shares of Celularity in the fourth quarter worth about $73,000. Two Sigma Investments LP bought a new position in Celularity during the fourth quarter valued at approximately $93,000. Finally, C V Starr & Co. Inc. bought a new position in Celularity during the fourth quarter valued at approximately $1,589,000. Institutional investors own 19.02% of the company’s stock.

Celularity Trading Down 1.6 %

CELU stock traded down $0.03 during midday trading on Monday, hitting $1.75. The company’s stock had a trading volume of 11,516 shares, compared to its average volume of 327,232. Celularity has a 12 month low of $1.00 and a 12 month high of $5.69. The company has a 50 day moving average of $1.84 and a two-hundred day moving average of $2.22.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.